PURPOSE: To evaluate the proportion of Korean ovarian cancer patients with a strong family history and the genetic status in such patients. METHODS AND PATIENTS: Pedigree analysis and genetic counseling were performed on 337 ovarian cancer patients in the National Cancer Center Korea between January 2005 and June 2008. Patients with a strong family history were defined as (1) patients with double primary ovarian and breast cancer and (2) ovarian cancer patients with one or more first-degree relatives with breast or ovarian cancer. Lymphocyte specimens from peripheral blood were processed for BRCA1 and BRCA2 by direct sequencing. RESULTS: Sixteen percent (54/337) of patients had a strong family history. Of the 54 patients with a strong family history, 40 patients (74%) accepted the genetic test. Thirteen deleterious mutations (11 in BRCA1 and 2 in BRCA2) were identified (33%). Twenty-three of 283 patients (8%) without a strong family history underwent genetic testing and two deleterious mutations in BRCA1 were identified (9%). Eight of 15 mutations (53%) were novel, and c.1041delAGCinsT and c.2081insC in the BRCA1 gene were recurrent in two patients. CONCLUSIONS: The proportion of Korean ovarian cancer patients with a strong family history was significant, and the prevalence of BRCA1 and BRCA2 mutations in such patients was high.
PURPOSE: To evaluate the proportion of Korean ovarian cancerpatients with a strong family history and the genetic status in such patients. METHODS AND PATIENTS: Pedigree analysis and genetic counseling were performed on 337 ovarian cancerpatients in the National Cancer Center Korea between January 2005 and June 2008. Patients with a strong family history were defined as (1) patients with double primary ovarian and breast cancer and (2) ovarian cancerpatients with one or more first-degree relatives with breast or ovarian cancer. Lymphocyte specimens from peripheral blood were processed for BRCA1 and BRCA2 by direct sequencing. RESULTS: Sixteen percent (54/337) of patients had a strong family history. Of the 54 patients with a strong family history, 40 patients (74%) accepted the genetic test. Thirteen deleterious mutations (11 in BRCA1 and 2 in BRCA2) were identified (33%). Twenty-three of 283 patients (8%) without a strong family history underwent genetic testing and two deleterious mutations in BRCA1 were identified (9%). Eight of 15 mutations (53%) were novel, and c.1041delAGCinsT and c.2081insC in the BRCA1 gene were recurrent in two patients. CONCLUSIONS: The proportion of Korean ovarian cancerpatients with a strong family history was significant, and the prevalence of BRCA1 and BRCA2 mutations in such patients was high.
Authors: L Sarantaus; P Vahteristo; E Bloom; A Tamminen; L Unkila-Kallio; R Butzow; H Nevanlinna Journal: Eur J Hum Genet Date: 2001-06 Impact factor: 4.246
Authors: Miguel de la Hoya; Ana Osorio; Javier Godino; Sara Sulleiro; Alicia Tosar; Pedro Perez-Segura; Cristina Fernandez; Raquel Rodríguez; Eduardo Díaz-Rubio; Javier Benítez; Peter Devilee; Trinidad Caldés Journal: Int J Cancer Date: 2002-02-01 Impact factor: 7.396
Authors: T Katagiri; F Kasumi; M Yoshimoto; T Nomizu; K Asaishi; R Abe; A Tsuchiya; M Sugano; S Takai; M Yoneda; T Fukutomi; K Nanba; M Makita; H Okazaki; K Hirata; M Okazaki; Y Furutsuma; Y Morishita; Y Iino; T Karino; H Ayabe; S Hara; T Kajiwara; S Houga; Y Miki Journal: J Hum Genet Date: 1998 Impact factor: 3.172
Authors: A M Martin; M A Blackwood; D Antin-Ozerkis; H A Shih; K Calzone; T A Colligon; S Seal; N Collins; M R Stratton; B L Weber; K L Nathanson Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: U S Khoo; H Y Ngan; A N Cheung; K Y Chan; J Lu; V W Chan; S Lau; I L Andrulis; H Ozcelik Journal: Hum Mutat Date: 2000-07 Impact factor: 4.878
Authors: J Boyd; Y Sonoda; M G Federici; F Bogomolniy; E Rhei; D L Maresco; P E Saigo; L A Almadrones; R R Barakat; C L Brown; D S Chi; J P Curtin; E A Poynor; W J Hoskins Journal: JAMA Date: 2000-05-03 Impact factor: 56.272
Authors: B Modan; P Hartge; G Hirsh-Yechezkel; A Chetrit; F Lubin; U Beller; G Ben-Baruch; A Fishman; J Menczer; J P Struewing; M A Tucker; S Wacholder Journal: N Engl J Med Date: 2001-07-26 Impact factor: 91.245
Authors: R Moslehi; W Chu; B Karlan; D Fishman; H Risch; A Fields; D Smotkin; Y Ben-David; J Rosenblatt; D Russo; P Schwartz; N Tung; E Warner; B Rosen; J Friedman; J S Brunet; S A Narod Journal: Am J Hum Genet Date: 2000-03-16 Impact factor: 11.025
Authors: Alexander Liede; Imtiaz A Malik; Zeba Aziz; Patricia de los Rios Pd; Elaine Kwan; Steven A Narod Journal: Am J Hum Genet Date: 2002-08-13 Impact factor: 11.025
Authors: Tamara S Roman; Stephanie B Crowley; Myra I Roche; Ann Katherine M Foreman; Julianne M O'Daniel; Bryce A Seifert; Kristy Lee; Alicia Brandt; Chelsea Gustafson; Daniela M DeCristo; Natasha T Strande; Lori Ramkissoon; Laura V Milko; Phillips Owen; Sayanty Roy; Mai Xiong; Ryan S Paquin; Rita M Butterfield; Megan A Lewis; Katherine J Souris; Donald B Bailey; Christine Rini; Jessica K Booker; Bradford C Powell; Karen E Weck; Cynthia M Powell; Jonathan S Berg Journal: Am J Hum Genet Date: 2020-08-26 Impact factor: 11.025
Authors: Edward S Y Wong; Sandhya Shekar; Marie Met-Domestici; Claire Chan; Melody Sze; Yoon Sim Yap; Steven G Rozen; Min-Han Tan; Peter Ang; Joanne Ngeow; Ann S G Lee Journal: NPJ Genom Med Date: 2016-01-13 Impact factor: 8.617
Authors: Young Jae Lee; Shin Wha Lee; Kyu Rae Kim; Kyung Hae Jung; Jong Won Lee; Yong Man Kim Journal: J Gynecol Oncol Date: 2016-08-08 Impact factor: 4.401